Prediction of Therapy Response and Prognosis in Leukemias by Flow Cytometric MDR Assays.
Multidrug resistance (MDR) is an unwanted phenomenon, that may cause therapy failure in several neoplasms including hematological malignancies. The purpose of any type of laboratory MDR assay is to reliably identify such patients and to provide useful data to clinicians with a relatively short turnaround time. MDR can be multicausal and several previous data identified a group of transmembrane proteins - the ATP-binding casette (ABC) proteins - that may be involved in MDR in various hematological malignancies. The prototype of these proteins is the P-glycoprotein (Pgp, MDR1, ABCB1) that is a seven-membrane spanning transmembrane protein capable of extruding several cytotoxic drugs that are of key importance in the treatment of hematological disorders. Similarly other ABC proteins - Multidrug resistance associated protein 1 (ABCC1) and breast cancer resistance protein (ABCG2) are both capable of pumping out cytotoxic drugs. Here, we present flow cytometric methods to identify MDR proteins by antigen and activity assays. The advantage of flow technology is the short turnaround time and its relative easiness compared to nucleic acid based technologies. However, for the activity assays, it should be noted, that these functional tests require live cells, thus adequate results can only be provided if the specimen transport can be completed within 6 hours of sample collection. Identification of MDR proteins provides prognostic information and may modulate therapy, thus signifies a clinically useful information in the evaluation of patients with leukemias.
Department of Laboratory Medicine, Medical and Health Science Center, University of Debrecen , Hungary.
János
J
Kappelmayer
Department of Laboratory Medicine, Medical and Health Science Center, University of Debrecen , Hungary.
Zsuzsa
Z
Hevessy
Solvo Biotechnology , Szeged, Hungary.
András
A
Apjok
Solvo Biotechnology , Szeged, Hungary.
Katalin Tauberné
KT
Jakab
drug-resistance; flow cytometry; leukemia
J Biol Chem. 1998 Jul 3;273(27):16631-4
9642211
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3511-6
11891276
Oncogene. 2003 Oct 20;22(47):7512-23
14576855
Leuk Lymphoma. 2002 Apr;43(4):711-7
12153155
J Biol Chem. 2003 Apr 18;278(16):13603-6
12609990
Br J Haematol. 2001 Nov;115(2):257-62
11703319
Blood. 1998 Dec 1;92(11):4296-307
9834236
Int J Hematol. 2007 Aug;86(2):166-73
17875533
J Clin Invest. 1997 Apr 15;99(8):1947-57
9109439
Biochemistry. 1998 Apr 7;37(14):5010-9
9538020
Adv Exp Med Biol. 1999;457:1-9
10500774
Malays J Pathol. 2008 Dec;30(2):87-93
19291917
Br J Haematol. 2001 Feb;112(2):308-14
11167823
Cancer Sci. 2003 Jan;94(1):15-21
12708468
Eur J Biochem. 2001 Apr;268(8):2416-20
11298761
Cancer. 2011 May 15;117(10 ):2156-62
21523728
Leukemia. 1995 Sep;9(9):1549-55
7658724
Toxicol Lett. 2003 Apr 11;140-141:133-43
12676459
Haematologica. 2005 Jan;90(1):54-9
15642669
Blood. 1996 Jun 1;87(11):4809-16
8639853
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70
9861027
Int J Cancer. 2006 May 1;118(9):2195-201
16331627
Assay Drug Dev Technol. 2007 Aug;5(4):541-50
17767422
Biochim Biophys Acta. 1994 May 11;1191(2):384-8
7909692
Mol Cell Biol. 1998 Jun;18(6):3604-11
9584201
Leukemia. 2002 May;16(5):833-9
11986944
Ann Hematol. 2007 May;86(5):329-37
17340137
Leukemia. 1997 Dec;11 Suppl 5:S10-4
9436932
Expert Rev Mol Diagn. 2004 Mar;4(2):209-17
14995907
Leuk Res. 2010 Jul;34(7):942-5
20122734
Blood. 2001 Jan 15;97(2):502-8
11154229
Biochim Biophys Acta. 1999 Dec 6;1461(2):347-57
10581366
Biochem Pharmacol. 2006 Apr 14;71(8):1162-74
16499877
Br J Haematol. 2005 Feb;128(3):324-32
15667534
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12908-13
9371774
Leuk Lymphoma. 2007 Aug;48(8):1556-60
17701587
Proc Natl Acad Sci U S A. 1987 May;84(9):3004-8
3472246
Biochim Biophys Acta. 1999 Dec 6;1461(2):359-76
10581367
Cytometry B Clin Cytom. 2006 May;70(3):189-96
16568474
J Biol Chem. 2003 Jan 31;278(5):3347-56
12424247